Tenon Medical launches smaller SI joint fusion implant to meet demand

LOS GATOS, Calif. - Tenon Medical, Inc. (NASDAQ:TNON), a medical device company with a market capitalization of $12.3 million, announced Tuesday the full commercial launch of its Catamaran SE SI Joint Fusion System, expanding its portfolio with a smaller implant option for sacroiliac joint fusion procedures. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 3.86, though it faces profitability challenges in the current market environment.

The new Catamaran SE Fixation Device features a reduced profile compared to the company’s original implant, providing surgeons with greater flexibility when treating patients with smaller SI joint anatomy or performing revision surgeries where space is limited. While the company shows promise in product development, InvestingPro data reveals the company faces operational challenges with a -12.6% revenue decline in the last twelve months. Subscribers can access 8 additional key ProTips and comprehensive analysis through the Pro Research Report.

Designed for minimally invasive procedures, the system includes a dedicated instrument set with a hand drill option for physicians who prefer manual drilling during implant site preparation.

"Having participated in the alpha launch of the Catamaran SE Fixation Device, I’ve been impressed with its performance - particularly its ability to provide immediate SI joint stabilization," said John Wrightson, MD, Interventional Pain Physician at Joshuason Rehabilitation and Pain Management in New Castle, Pennsylvania.

The Catamaran SI Joint Fixation Device is a single-piece titanium implant with two pontoons connected by an osteotome bridge, engineered to stabilize the SI joint. According to the company’s press release, more than 1,000 devices have been implanted to date for various SI joint conditions.

Tenon Medical reports it has expanded inventories of both implants and instrumentation, supported by enhanced commercial leadership and field support gained through its recent SiVantage acquisition.

The company states the system is designed to be placed via a minimally invasive approach into the dense cortical bone of the sacrum and ilium. Despite recent product developments, the company’s financial health score stands at 2.1 (FAIR) according to InvestingPro metrics, with the company holding more cash than debt on its balance sheet, positioning it for potential growth opportunities in the medical device market.

In other recent news, Tenon Medical Inc. reported its financial results for the second quarter of 2025, revealing a decline in revenue but an improved net loss compared to the previous year. Despite the dip in revenue, the company experienced a positive market response, as evidenced by a surge in its stock. The increase in investor confidence is attributed to Tenon Medical’s strategic acquisitions and product innovations. Notably, the company received FDA clearance for new medical devices, which contributed to a promising outlook for future quarters. These developments indicate the company’s efforts to strengthen its market position. Additionally, the market’s reaction suggests optimism about the company’s strategic direction. This recent performance highlights Tenon Medical’s adaptability in a competitive industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.